Skip to content Skip to navigation

Biyao Zou

Biyao Zou

Biyao Zou

About

Hepatocellular carcinoma (HCC) is the second leading cause of cancer mortality worldwide. Early HCC diagnosis increases survival, but the current HCC surveillance tests (ultrasound and serum alpha-fetoprotein) have suboptimal accuracy. We have integrated meta-analysis and microarray data to identify certain methylated cell-free DNA biomarkers for HCC. I will employ giant magnetoresistive biosensor technology to develop a rapid and low-cost multiplexed assay to screen and quantify these biomarkers, and then validate the accuracy of this HCC biomarker diagnostic in a well-characterized multicenter cohort. This interdisciplinary approach of computational modeling, bioinformatics, and biosensing techniques will pave the way to cost-effective and portable HCC surveillance based on highly accurate HCC biomarkers, and will improve HCC survival.